{"id":"https://openalex.org/W2592521826","doi":"https://doi.org/10.1182/blood.v128.22.58.58","title":"Implications of Concurrent Ibrutinib Therapy on CAR T-Cell Manufacturing and Phenotype and on Clinical Outcomes Following CD19-Targeted CAR T-Cell Administration in Adults with Relapsed/Refractory CLL","display_name":"Implications of Concurrent Ibrutinib Therapy on CAR T-Cell Manufacturing and Phenotype and on Clinical Outcomes Following CD19-Targeted CAR T-Cell Administration in Adults with Relapsed/Refractory CLL","publication_year":2016,"publication_date":"2016-12-02","ids":{"openalex":"https://openalex.org/W2592521826","doi":"https://doi.org/10.1182/blood.v128.22.58.58","mag":"2592521826"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v128.22.58.58","doi":"https://doi.org/10.1182/blood.v128.22.58.58","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v128.22.58.58","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5040703931","display_name":"Mark Blaine Geyer","orcid":"https://orcid.org/0000-0001-5248-9117","observed_orcids":["https://orcid.org/0000-0001-5248-9117"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark Blaine Geyer","raw_affiliation_strings":["Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101838284","display_name":"Jae H. Park","orcid":"https://orcid.org/0000-0002-2903-5130","observed_orcids":["https://orcid.org/0000-0002-2903-5130","https://orcid.org/0009-0003-2678-9513"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jae H. Park","raw_affiliation_strings":["Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY","Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]},{"raw_affiliation_string":"Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036831073","display_name":"Isabelle Rivi\u00e8re","orcid":"https://orcid.org/0000-0002-7363-3963","observed_orcids":["https://orcid.org/0000-0002-7363-3963"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Isabelle Riviere","raw_affiliation_strings":["Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062885345","display_name":"Brigitte S\u00e9n\u00e9chal","orcid":"https://orcid.org/0000-0003-2467-5152","observed_orcids":["https://orcid.org/0000-0003-2467-5152"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Brigitte Senechal","raw_affiliation_strings":["Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101691045","display_name":"Xiuyan Wang","orcid":"https://orcid.org/0000-0002-1551-3330","observed_orcids":["https://orcid.org/0000-0002-1551-3330"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Xiuyan Wang","raw_affiliation_strings":["Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011077747","display_name":"Terence J. Purdon","orcid":"https://orcid.org/0009-0009-7824-7760","observed_orcids":["https://orcid.org/0009-0009-7824-7760","https://orcid.org/0000-0002-2083-1667"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Terence J. Purdon","raw_affiliation_strings":["Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059625599","display_name":"Michel Sadelain","orcid":"https://orcid.org/0000-0002-9031-8025","observed_orcids":["https://orcid.org/0000-0002-9031-8025"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michel W. Sadelain","raw_affiliation_strings":["Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5065556543","display_name":"Renier J. Brentjens","orcid":"https://orcid.org/0000-0002-3364-5388","observed_orcids":["https://orcid.org/0000-0002-3364-5388"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Renier J. Brentjens","raw_affiliation_strings":["Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY","Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY","Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]},{"raw_affiliation_string":"Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]},{"raw_affiliation_string":"Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5011077747","https://openalex.org/A5062885345","https://openalex.org/A5101691045"],"corresponding_institution_ids":["https://openalex.org/I1334819555"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":1.3606,"has_fulltext":false,"cited_by_count":13,"citation_normalized_percentile":{"value":0.83218755,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"128","issue":"22","first_page":"58","last_page":"58"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.8163999915122986,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.8163999915122986,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.17630000412464142,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ibrutinib","display_name":"ibrutinib","score":0.972000002861023},{"id":"https://openalex.org/keywords/cd19-car-t-cells","display_name":"CD19 CAR T cells","score":0.9160000085830688},{"id":"https://openalex.org/keywords/relapsed-refractory-chronic-lymphocytic-leukemia","display_name":"relapsed/refractory chronic lymphocytic leukemia","score":0.9620000123977661},{"id":"https://openalex.org/keywords/car-t-cell-manufacturing","display_name":"CAR T cell manufacturing","score":0.7979999780654907},{"id":"https://openalex.org/keywords/conditioning-chemotherapy","display_name":"conditioning chemotherapy","score":0.6570000052452087},{"id":"https://openalex.org/keywords/cytokine-release-syndrome","display_name":"cytokine release syndrome","score":0.515999972820282},{"id":"https://openalex.org/keywords/cytokine-levels","display_name":"cytokine levels","score":0.5009999871253967},{"id":"https://openalex.org/keywords/t-cell-phenotype","display_name":"T cell phenotype","score":0.42100000381469727},{"id":"https://openalex.org/keywords/complete-response","display_name":"complete response","score":0.42500001192092896},{"id":"https://openalex.org/keywords/p53-loss","display_name":"p53 deficiency","score":0.5839999914169312},{"id":"https://openalex.org/keywords/b-cell-non-hodgkin-lymphoma","display_name":"B-cell non-Hodgkin lymphoma","score":0.8080000281333923},{"id":"https://openalex.org/keywords/retroviral-vectors","display_name":"retroviral vectors","score":0.4970000088214874}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7017797231674194},{"id":"https://openalex.org/C2777371436","wikidata":"https://www.wikidata.org/wiki/Q3237071","display_name":"Leukapheresis","level":4,"score":0.6333834528923035},{"id":"https://openalex.org/C3875195","wikidata":"https://www.wikidata.org/wiki/Q5099363","display_name":"Chimeric antigen receptor","level":4,"score":0.5547882318496704},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.5015721321105957},{"id":"https://openalex.org/C2780850621","wikidata":"https://www.wikidata.org/wiki/Q3961647","display_name":"Cytokine release syndrome","level":5,"score":0.4840054214000702},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.47444450855255127},{"id":"https://openalex.org/C2778957590","wikidata":"https://www.wikidata.org/wiki/Q798033","display_name":"CD19","level":3,"score":0.4304003119468689},{"id":"https://openalex.org/C148125776","wikidata":"https://www.wikidata.org/wiki/Q1622348","display_name":"CD28","level":4,"score":0.4168719947338104},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3566083312034607},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3470310568809509},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.33906978368759155},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.3223589062690735},{"id":"https://openalex.org/C28328180","wikidata":"https://www.wikidata.org/wiki/Q48196","display_name":"Stem cell","level":2,"score":0.23957115411758423},{"id":"https://openalex.org/C10205521","wikidata":"https://www.wikidata.org/wiki/Q4035578","display_name":"CD34","level":3,"score":0.1576598584651947},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.1392328441143036},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v128.22.58.58","doi":"https://doi.org/10.1182/blood.v128.22.58.58","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v128.22.58.58","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2953039146","https://openalex.org/W3007925874","https://openalex.org/W2901026782","https://openalex.org/W2296829012","https://openalex.org/W2592891095","https://openalex.org/W2912567539","https://openalex.org/W2937580508","https://openalex.org/W2907015766","https://openalex.org/W2934961572","https://openalex.org/W2748623468"],"abstract_inverted_index":{"Abstract":[0],"Introduction:":[1],"CD19-targeted":[2,49,101,153],"chimeric":[3],"antigen":[4],"receptor-modified":[5],"(CAR)":[6],"T":[7,51,72,85,103,133,142,155,172,226,263,276,309,330,341,381,401,419,438,450,461,547,600,633,647,687,705],"cells":[8,86,156,173,382,402,420,548],"have":[9,45,77],"demonstrated":[10,395],"considerable":[11,58],"therapeutic":[12],"efficacy":[13,59,108,709],"in":[14,27,64,93,109,146,348,383,466,478,502,590,617,657,690,710,716],"patients":[15],"(pts)":[16],"with":[17,42,66,90,123,126,159,176,201,206,209,240,281,289,317,368,403,519,538,542,627,712],"relapsed":[18],"and/or":[19,136,216,294],"refractory":[20],"(R/R)":[21],"B":[22],"cell":[23,52,73,104,134,143,227,264,277,310,331,342,439,601,634,648,688,706],"ALL":[24],"(B-ALL),":[25],"resulting":[26],"rapid":[28],"and":[29,99,106,171,187,189,224,258,261,307,328,414,431,453,470,497,529,544,595,655,692,702,708],"often":[30],"durable":[31],"complete":[32],"responses":[33,643],"(CR).":[34],"In":[35,531],"contrast,":[36],"a":[37,61,177,181,184,230,396,404],"smaller":[38],"subset":[39],"of":[40,83,131,140,152,214,220,378,399,417,476,514,534,559,653,756],"pts":[41,65,89,168,200,205,239,268,316,351,384,444,455,469,481,488,507,537,570,588,620,654,711],"R/R":[43,67,160,282,318,713],"CLL":[44,124,161,207,241,283,319,539,714],"achieved":[46,549],"CR":[47,592],"following":[48,644],"CAR":[50,102,141,154,182,225,262,275,308,329,449,460,546,599,632,646,686,704],"therapy.":[53],"Ibrutinib":[54],"(IBR),":[55],"which":[56],"has":[57],"as":[60],"single":[62],"agent":[63],"CLL,":[68],"may":[69,629,640,672,683],"modulate":[70],"antitumor":[71,107,642],"immune":[74],"responses.":[75],"Others":[76],"observed":[78,603],"enhanced":[79],"ex":[80,344],"vivo":[81,345,691],"expansion":[82,343,689,707],"autologous":[84,132],"collected":[87],"from":[88],"IBR":[91,127,210,290,353,389,628,639,671],"exposure":[92],"response":[94,551],"to":[95,199,297,504,604,697],"CD3/CD28":[96],"bead":[97],"stimulation,":[98],"improved":[100],"engraftment":[105],"human":[110],"xenograft":[111],"models":[112],"(Fraietta":[113],"et":[114],"al.,":[115],"Blood,":[116],"2016).":[117],"Herein,":[118],"we":[119,233],"report":[120],"on":[121,243,352,358,388,393,472,664,752],"adults":[122,158],"treated":[125,208,242,541],"at":[128,211,274,291,360,593],"the":[129,138,212,218,349,355,473,618,699],"time":[130,139,213,219,372],"collection":[135,386],"around":[137,217],"infusion":[144,278,311,477],"enrolled":[145,536],"our":[147],"phase":[148],"I":[149],"clinical":[150],"trial":[151],"for":[157,500,580],"or":[162,298,758],"B-cell":[163],"NHL":[164],"(NCT00466531).":[165],"Methods:":[166],"Eligible":[167],"underwent":[169,287],"leukapheresis":[170,215,292,361],"were":[174,254,615],"transduced":[175],"retroviral":[178],"vector":[179,610],"encoding":[180],"comprising":[183],"CD19-specific":[185],"scFv":[186],"CD28":[188],"CD3\u03b6":[190],"signaling":[191],"domains":[192],"(19-28z).":[193],"The":[194],"present":[195],"analysis":[196],"is":[197,606],"limited":[198],"CLL.":[202],"We":[203],"identified":[204,235],"conditioning":[221],"chemotherapy":[222],"(CCT)":[223],"infusion.":[228,265,332],"As":[229],"control":[231],"group,":[232],"additionally":[234,508],"all":[236,467],"evaluable":[237,315],"IBR-na\u00efve":[238,321,454,484,585],"this":[244],"study.":[245],"Response":[246],"was":[247,346,566],"assessed":[248],"by":[249,613],"NCI-WG":[250],"criteria.":[251],"Cytokine":[252],"levels":[253,513,612],"measured":[255],"prospectively":[256],"before":[257],"after":[259],"CCT":[260,300,323,543,658,678],"Results:":[266],"5":[267,533],"(male,":[269],"n=3),":[270],"median":[271,338,370,446,457,511],"age":[272],"58":[273],"(range,":[279],"43-66)":[280],"(TP53":[284],"loss,":[285],"n=2)":[286,327],"therapy":[288,626],"(n=4)":[293],"immediately":[295],"prior":[296,668],"through":[299,322],"(cyclophosphamide":[301],"[Cy],":[302],"n=2;":[303,557],"fludarabine":[304],"[Flu]+Cy,":[305],"n=3)":[306],"(n=5).":[312],"6":[313],"additional":[314],"remained":[320],"(Cy,":[324],"n=4;":[325],"bendamustine,":[326],"A":[333],"non-significant":[334],"trend":[335],"toward":[336],"greater":[337,397,510],"cumulative":[339],"fold":[340],"noted":[347],"4":[350],"(vs":[354,390,482,489],"7":[356],"not":[357,392],"IBR)":[359,394],"(374":[362],"[171-1518]":[363],"vs":[364,374,411,428,435,584,681],"160":[365],"[49-468],":[366],"p=0.13),":[367],"similar":[369],"manufacturing":[371],"(13.5":[373],"15":[375],"days).":[376],"End":[377],"process":[379],"(EOP)":[380],"undergoing":[385],"while":[387],"those":[391],"fraction":[398,416],"CD8+CAR+":[400,425],"CD62L+CD127+":[405],"(central":[406],"memory)":[407],"phenotype":[408],"(mean":[409,426,433],"29.0":[410],"4.3%,":[412],"p=0.10)":[413],"decreased":[415],"CD62L-":[418],"(effector/effector":[421],"memory":[422],"phenotype)":[423],"across":[424],"26.5":[427],"54.4%,":[429],"p=0.06)":[430],"CD4+CAR+":[432],"24.0":[434],"57.8%,":[436],"p=0.03)":[437],"subsets":[440],"(Fig":[441],"1).":[442],"IBR-treated":[443,480,487,506,569,583],"received":[445,456],"1x107":[447,458],"19-28z+":[448,459],"cells/kg":[451,462],"(3x106-3x107/kg)":[452],"(6x106-4x107/kg).":[463],"Fevers":[464],"developed":[465,494],"11":[468,535],"began":[471],"first":[474],"day":[475],"4/5":[479,567],"2/6":[483],"pts);":[485],"2/5":[486],"0/6":[490],"IBR-":[491],"na\u00efve":[492],"pts)":[493],"severe":[495],"CRS":[496],"required":[498],"vasopressors":[499],"hypotension":[501],"addition":[503],"tocilizumab.":[505],"exhibited":[509],"peak":[512,609],"multiple":[515],"immunoregulatory":[516],"cytokines":[517],"associated":[518],"CRS,":[520,674],"including":[521],"IL-6,":[522],"IL-10,":[523],"IL-2,":[524],"IL-5,":[525],"IFN-\u03b3,":[526],"FLT3L,":[527],"fractalkine,":[528],"GM-CSF.":[530],"total,":[532],"(45%)":[540],"19-28z":[545,645],"objective":[550],"(minimal":[552],"residual":[553],"disease":[554],"[MRD]-":[555],"CR,":[556,561,573,576],"maintenance":[558],"MRD+":[560,575],"n=1;":[562],"PR,":[563],"n=2);":[564],"ORR":[565,581],"among":[568],"(1":[571],"MRD-":[572,591],"1":[574],"2":[577,587,619],"PR;":[578],"p=0.08":[579],"between":[582],"pts).":[586],"remain":[589],"16":[594],"50":[596],"months.":[597],"Maximal":[598],"persistence":[602],"date":[605],"159":[607],"days;":[608],"copy":[611],"qPCR":[614],"highest":[616],"attaining":[621],"MRD-negative":[622],"CR.":[623],"Conclusions:":[624],"Prior":[625,636],"influence":[630],"EOP":[631],"phenotypes.":[635],"\u00b1":[637,669],"concurrent":[638,670],"improve":[641],"administration,":[649],"though":[650,675],"small":[651],"numbers":[652],"differences":[656],"regimens":[659],"limit":[660],"firm":[661],"conclusions":[662],"based":[663],"these":[665],"data.":[666],"Additionally,":[667],"amplify":[673],"more":[676],"intensive":[677],"(e.g.":[679],"Flu/Cy":[680],"Cy)":[682],"also":[684],"enhance":[685,703],"intensify":[693],"CRS.":[694],"Further":[695],"strategies":[696],"overcome":[698],"inhibitory":[700],"microenvironment":[701],"are":[715],"preparation.":[717],"Disclosures":[718],"Park:":[719],"Amgen:":[720],"Consultancy;":[721],"Genentech/Roche:":[722],"Research":[723,728,738,761],"Funding;":[724],"Juno":[725],"Therapeutics:":[726,731,741,749],"Consultancy,":[727,732,742,750],"Funding.":[729,739,762],"Riviere:Juno":[730],"Equity":[733,743],"Ownership,":[734,744],"Patents":[735,745],"&":[736,746],"Royalties,":[737],"Sadelain:Juno":[740],"Royalties.":[747],"Brentjens:Juno":[748],"Membership":[751],"an":[753],"entity's":[754],"Board":[755],"Directors":[757],"advisory":[759],"committees,":[760]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":3}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2017-03-16T00:00:00"}